Emer-Log（エマログ）　2023年秋季増刊号　救急・ICUの薬剤マスターブック

出版社： メディカ出版
発行日： 2023-10-05
分野： 臨床医学：一般  >  雑誌
ISBN： 9784840479783
ISSN： 24344559
雑誌名：
特集： 救急・ICUの薬剤マスターブック
電子書籍版： 2023-10-05 （電子書籍版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

3,520 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,520 円(税込)

購入する
特記事項：
  • 【電子書籍】著作権者の意向により電子版では非掲載の画像がございます

目次

  • 特集　似ている薬の選択と根拠がわかる
    　　　救急・ICUの薬剤マスターブック

    【1章】薬剤師が教える！救急・ICU薬剤のキホン
    ■1　薬物動態
    ■2　薬物の用量の考え方
    ■3　薬物相互作用
    ■4　配合変化・配合禁忌
    ■5　薬物血中濃度モニタリング
    ■6　小児と薬剤
    ■7　妊婦と薬剤
    ■8　高齢者と薬剤

    【2章】ケースでわかる！救急・ICU薬剤の使い分け
    ■1　抗精神病薬・睡眠薬
    　　　―糖尿病既往のあるせん妄患者での選択
    　　　ハロペリドール／クエチアピン／ラメルテオン
    ■2　オピオイド
    　　　―腎機能が低下したがん性疼痛患者での選択
    　　　フェンタニル／モルヒネ
    ■3　抗てんかん薬
    　　　―痙攣性てんかん重積患者での選択
    　　　ジアゼパム／ロラゼパム／フェニトイン／ホスフェニトイン
    ■4　昇圧薬
    　　　―脊髄損傷で入院中の敗血症性ショック患者での選択
    　　　ノルアドレナリン／ドパミン／バソプレシン／アドレナリン
    ■5　輸液
    　　　―腹腔内感染による敗血症性ショック患者での選択
    　　　生理食塩液／酢酸リンゲル液／アルブミン製剤
    ■6　利尿薬
    　　　―体液貯留のある急性心不全患者での選択
    　　　フロセミド／トルバプタン／カルペリチド
    ■7　抗不整脈薬
    　　―除細動抵抗性の心室細動患者での選択
    　　　アミオダロン／リドカイン／ランジオロール
    ■8　カルシウム拮抗薬
    　　―虚血性心疾患既往のある心房細動患者での選択
    　　　ニカルジピン／ジルチアゼム／ベラパミル
    ■9　β遮断薬
    　　　―喘息既往のある心筋梗塞患者での選択
    　　　ビソプロロール／カルベジロール／プロプラノロール
    ■10　経口抗凝固薬
    　　　―腎機能障害のある、フェニトイン服用中の心房細動患者での選択
    　　　ワルファリン／ダビガトラン／アピキサバン
    ■11　抗血小板薬
    　　　―透析中の脳梗塞急性期患者での選択
    　　　アスピリン／クロピドグレル／シロスタゾール
    ■12　抗凝固薬に対する拮抗薬
    　　　―ワルファリン内服中の頭部外傷患者での選択
    　　　乾燥濃縮人プロトロンビン複合体／イダルシズマブ／アンデキサネット アルファ
    ■13　高カリウム血症治療薬
    　　　―腸閉塞既往のある高カリウム血症患者での選択
    　　　ポリスチレンスルホン酸カルシウム／ジルコニウムシクロケイ酸ナトリウム水和物／
    　　　グルコース・インスリン（GI）療法
    ■14　経口血糖降下薬
    　　　―うっ血性心不全、腎機能低下の糖尿病患者での選択
    　　　メトホルミン／ダパグリフロジン／シタグリプチン
    ■15　抗MRSA薬
    　　　―腎機能障害のある、肺炎による敗血症性ショック患者での選択
    　　　バンコマイシン／ダプトマイシン／リネゾリド
    ■16　抗真菌薬
    　　　―腎機能障害のある、フェニトイン服用中のカンジダ血症患者での選択
    　　　ホスフルコナゾール／ミカファンギン／アムホテリシンB製剤
    ■17　抗凝固薬
    　　　―内科系疾患入院患者におけるDVT予防としての選択
    　　　ヘパリンカルシウム／エノキサパリンナトリウム／エドキサバン
    ■18　ストレス潰瘍予防薬
    　　　―出血リスクの高い、肝機能・腎機能障害患者での選択
    　　　オメプラゾール／ファモチジン／スクラルファート

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 薬剤師が教える ! 救急・ICU薬剤のキホン

P.17 掲載の参考文献
1) De Paepe, P. et al. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet. 41(14), 2002, 1135-51.
PubMed
2) Smith, BS. et al. Introduction to drug pharmacokinetics in the critically ill patient. Chest. 141(5), 2012, 1327-36.
PubMed
3) Bracco, D. et al. Pharmacokinetic variability of extended interval tobramycin in burn patients. Burn. 34(6), 2008, 791-6.
PubMed
4) Goncalves-Pereira, J. et al. Antibiotics in critically ill patients:a systematic review of the pharmacokinetics of β-lactams. Crit Care. 15(5), 2011, R206.
 
5) Huang, Y. et al. Association Between Pathophysiology and Volume of Distribution Among Patients With Sepsis or Septic Shock Treated With Imipenem:A Prospective Cohort Study. J Infect Dis. 221(Suppl 2), 2020, S272-8.
PubMed
6) Malacrida, R. et al. Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients. Crit Care Med. 20(8), 1992, 1123-6.
PubMed
7) van den Broek, MP. et al. Effects of hypothermia on pharmacokinetics and pharmacodynamics:a systematic review of preclinical and clinical studies. Clin Pharmacokinet. 49(5), 2010, 277-94.
PubMed
8) Harbrecht, BG. et al. Cytochrome P-450 activity is differentially altered in severely injured patients. Crit Care Med. 33(3), 2005, 541-6.
PubMed
9) Morgan, ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev. 29(4), 1997, 1129-88.
PubMed
10) Kawano, Y. et al. Augmented renal clearance in Japanese intensive care unit patients:a prospective study. J Intensive Care. 4, 2016, 62.
PubMed
11) Bilbao-Meseguer, I. et al. Augmented Renal Clearance in Critically Ill Patients:A Systematic Review. Clin Pharmacokinet. 57(9), 2018, 1107-21.
PubMed
P.24 掲載の参考文献
1) Bohte, R. et al. Levels of azithromycin and alpha-1 acid glycoprotein in serum in patients with community-acquired pneumonia. Antimicrob Agents Chemother. 39(12), 1995, 2801-2.
PubMed
2) Ronco, C. et al. Acute kidney injury. Lancet. 394(10212), 2019, 1949-64.
PubMed
3) Uchino, S. et al. Acute renal failure in critically ill patients:a multinational, multicenter study. JAMA. 294(7), 2005, 813-8.
PubMed
4) Gilbert, DN. et al. eds. The Sanford Guide to Antimicrobial Therapy 2023, Spiral ed. ANTIMICROBIAL THERAPY, INCORPO, 2023, 339p.
 
5) Johns Hopkins Antibiotic Guide. https://play.google.com/store/apps/details?id=com.unbound.android.ubjhl&hl=ja&gl=US (accessed 2023-08-07)
 
6) Shah, S. et al. Pharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient. J Intensive Care Soc. 16(2), 2015, 147-53.
 
7) Taccone, FS. et al. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 14(4), 2010, R126.
 
8) 日本化学療法学会・日本TDM学会. 抗菌薬TDMガイドライン. 2022
 
P.32 掲載の参考文献
1) 田中博和. 薬物の相互作用とその機序. 月刊ナーシング. 42(12), 2022, 10-7.
 
2) Ahonen, J. et al. Interaction between fluconazole and midazolam in intensive care patients. Acta Anaesthesiol Scand. 43(5), 1999, 509-14.
PubMed
3) 杉山正康編著. 薬の相互作用としくみ. 東京, 日経BP社, 2016, 728p.
 
4) 薬物動態の変化を伴う薬物相互作用2016. Pharma Tribune. 東京, メディカルトリビューン, 2016. https://medical-tribune.co.jp/news/poster_A4.pdf (accessed 2023-08-01)
 
P.39 掲載の参考文献
1) 赤瀬朋秀ほか編. 根拠からよくわかる注射薬・輸液の配合変化. Ver.2. 東京, 羊土社, 2017, 246p.
 
2) Information for healthcare professionals:Ceftriaxone (marketed as Rocephin). Food and Drug Administration, 2007.
 
P.43 掲載の参考文献
1) van Hal, SJ. et al. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 57(2), 2013, 734-44.
PubMed
2) Hoste, EA. et al. Epidemiology of acute kidney injury in critically ill patients:the multinational AKI-EPI study. Intensive Care Med. 41(8), 2015, 1411-23.
 
P.50 掲載の参考文献
1) 小児てんかん重積状態・けいれん重積状態治療ガイドライン改訂ワーキンググループ編. 小児てんかん重積状態・けいれん重積状態治療ガイドライン2023. 日本小児神経学会監修. 東京, 診断と治療社, 2023, 18, 33.
 
2) 小児てんかん重積状態・けいれん重積状態治療ガイドライン改訂ワーキンググループ編. 小児てんかん重積状態・けいれん重積状態治療ガイドライン2023. 日本小児神経学会監修. 東京, 診断と治療社, 2023, 220p.
 
3) 「てんかん診療ガイドライン」作成委員会編. てんかん診療ガイドライン2018. 日本神経学会監修. 東京, 医学書院, 2018, 77-8.
 
4) 小児急性脳症診療ガイドライン策定委員会編. 小児急性脳症診療ガイドライン2016. 東京, 診断と治療社, 2016, 40-5.
 
5) Taketomo, CK. et al. Pediatric & Neonatal Dosage Handbook, 29th ed. Lexi-Comp, Inc. 2022.
 
6) 日本小児臨床薬理学会教育委員会編. 小児薬物療法テキストブック. 板橋家頭夫総監修. 東京, じほう, 2017, 27-9.
 
7) 国立成育医療研究センター薬剤部編. 小児科領域の薬剤業務ハンドブック第2版. 東京, じほう, 2016, 74-7.
 
P.57 掲載の参考文献
1) 佐藤孝道. 実践 妊娠と薬. 第2版. 林昌洋ほか編. 東京, じほう, 2010, 3.
 
2) 日本産科婦人科学会・日本産婦人科医会. 産婦人科診療ガイドライン:産科編2020. 東京, 日本産科婦人科学会, 2020, 60-1.
 
3) 伊藤真也ほか編. 薬物治療コンサルテーション:妊娠と授乳. 改訂2版. 東京, 南山堂, 2014, 667p.
 
4) JSEPTIC薬剤師部会. 病棟・ICU・ERで使えるクリティカルケア薬 Essence & Practice. 東京, じほう, 2021, 1072p.
 
P.64 掲載の参考文献
1) 寺島秀夫. Part II. 栄養療法実践編 4. 過剰栄養投与の有害性とモニタリング:重症患者の栄養療法はoverfeedingの正しい理解から始まる:特集 栄養療法アップデート 前編. INTENSIVIST. 11(2), 2019, 329.
 
2) Stevens, RD. et al. A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med. 37(10 Suppl), 2009, S299-308.
 
3) 神津玲ほか. Keyword 3 ICU-AWおよびPICSとリハビリテーション:特集 急性期・回復期・生活期 みんながつながる 呼吸管理のフロントライン. Respica. (17)1, 2019, 27.
 
4) 日本老年医学会 日本医療研究開発機構研究費・高齢者の薬物治療の安全性に関する研究研究班編. 高齢者の安全な薬物療法ガイドライン2015. 東京, 日本老年医学会, 2015, 172p.
 
5) Singer, P. et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr. 38(1), 2019, 48-79.
PubMed
6) Schuetz, P. et al. Individualised nutritional support in medical inpatients at nutritional risk:a randomised clinical trial. Lancet. 393(10188), 2019, 2312-21.
 
7) 佐藤武揚ほか. 集中治療患者におけるrefeeding syndrome. 外科と代謝・栄養. 50(6), 2016, 321-6.
Medical*Online
8) Rady, MY. et al. Influence of individual characteristics on outcome of glycemic control in intensive care unit patients with or without diabetes mellitus. Mayo Clin Proc. 80(12), 2005, 1558-67.
PubMed
9) Krinsley, JS. Glycemic variability:a strong independent predictor of mortality in critically ill patients. Crit Care Med. 36(11), 2008, 3008-13.
 
10) 日本集中治療医学会重症患者の栄養管理ガイドライン作成委員会. 日本版重症患者の栄養療法ガイドライン. 日本集中治療医学会雑誌. 23(2), 2016, 185-281.
 
11) NICE-SUGAR Study Investigators. Finfer, S. et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 360(13), 2009, 1283-97.
 
12) 小谷穣治(特集編集). エキスパートに学ぶ栄養管理のすべて. 救急・集中治療. 30(1), 2018, 39-46.
 

2章 ケースでわかる ! 救急・ICU薬剤の使い分け

P.70 掲載の参考文献
1) Ely, EW. et al. Evaluation of delirium in critically ill patients:validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med. 29(7), 2001, 1370-9.
PubMed
2) Milbrandt, EB. et al. Costs associated with delirium in mechanically ventilated patients. Crit Care Med. 32(4), 2004, 955-62.
PubMed
3) Ely, EW. et al. The impact of delirium in the intensive care unit on hospital length of stay. Intensive Care Med. 27(12), 2001, 1892-900.
PubMed
4) Lat, I. et al. The impact of delirium on clinical outcomes in mechanically ventilated surgical and trauma patients. Crit Care Med. 37(6), 2009, 1898-905.
PubMed
5) Ely, EW. et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 291(14), 2004, 1753-62.
PubMed
6) Pisani, MA. et al. Days of delirium are associated with 1-year mortality in an older intensive care unit population. Am J Respir Crit Care Med. 180(11), 2009, 1092-7.
 
7) Jacobi, J. et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 30(1), 2002, 119-41.
PubMed
8) Riker, RR. et al. Continuous infusion of haloperidol controls agitation in critically ill patients. Crit Care Med. 22(3), 1994, 433-40.
PubMed
9) Seneff, MG. et al. Use of haloperidol infusions to control delirium in critically ill adults. Ann Pharmacother. 29(7-8), 1995, 690-3.
 
10) Tesar, GE. et al. Use of high-dose intravenous haloperidol in the treatment of agitated cardiac patients. J Clin Psychopharmacol. 5(6), 1985, 344-7.
PubMed
11) Barr, J. et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 41(1), 2013, 263-306.
PubMed
12) Lonergan, E. et al. Antipsychotics for delirium. Cochrane Database Syst Rev. 18(2), 2007, CD005594.
 
13) Devlin, JW. et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 46(9), 2018, e825-e873.
PubMed
14) 医薬品インタビューフォーム. セロクエル. https://amn.astellas.jp/content/jp/amn/jp/ja/common/pdfviewer.html/content/dam/jp/amn/ja/di/doc/Pdfs/DocNo202311649_y.pdf (accessed 2023-07-18)
 
15) Hatta, K. et al. Preventive effects of ramelteon on delirium:a randomized placebo-controlled trial. JAMA Psychiatry. 71(4), 2014, 397-403.
PubMed
16) Nishikimi, M. et al. Effect of Administration of Ramelteon, a Melatonin Receptor Agonist, on the Duration of Stay in the ICU:A Single-Center Randomized Placebo-Controlled Trial. Crit Care Med. 46(7), 2018, 1099-105.
PubMed
17) Ohta, T. et al. Melatonin receptor agonists for treating delirium in elderly patients with acute stroke. J Stroke Cerebrovasc Dis. 22(7), 2013, 1107-10.
PubMed
18) Tsuda, A. et al. Ramelteon for the treatment of delirium in elderly patients:a consecutive case series study. Int J Psychiatry Med. 47(2), 2014, 97-104.
PubMed
19) Maldonado, JR. et al. Dexmedetomidine and the reduction of postoperative delirium after cardiac surgery. Psychosomatics. 50(3), 2009, 206-17.
PubMed
20) Riker, RR. et al. Dexmedetomidine vs midazolam for sedation of critically ill patients:a randomized trial. JAMA. 301(5), 2009, 489-99.
PubMed
21) Jakob, SM. et al. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation:two randomized controllxed trials. JAMA. 307(11), 2012, 1151-60.
 
22) Reade, MC. et al. Effect of dexmedetomidine added to standard care on ventilator-free time in patients with agitated delirium:A randomized clinical trial. JAMA. 315(14), 2016, 1460-8.
PubMed
P.77 掲載の参考文献
1) Pain terms:a list with definitions and notes on usage. Recommended by the IASP Subcommittee on Taxonomy. Pain. 6(3), 1979, 249.
PubMed
2) Chanques, G. et al. A prospective study of pain at rest:incidence and characteristics of an unrecognized symptom in surgical and trauma versus medical intensive care unit patients. Anesthesiology. 107(5), 2007, 858-60.
PubMed
3) Stanik-Hutt, JA. et al. Pain experiences of traumatically injured patients in acritical care setting. Am J Crit Care. 10(4), 2001, 252-9.
 
4) Gelinas, C. Management of pain in cardiac surgery ICU patients:have we improved over time?. Intensive Crit Care Nurs. 23(5), 2007, 298-303.
PubMed
5) Ballard, KS. Identification of environmental stressors for patients in a surgical intensive care unit. Issues Ment Health Nurs. 3, 1981, 89-108.
 
6) Rotondi, AJ. et al. Patients' recollections of stressful experiences while receiving prolonged mechanical ventilation in an intensive care unit. Crit Care Med. 30(4), 2002, 746-52.
 
7) 日本集中治療医学会J-PADガイドライン作成委員会. 日本版・集中治療室における成人重症患者に対する痛み・不穏・せん妄管理のための臨床ガイドライン. 日本集中治療医学会雑誌. 21(5), 2014, 539-79.
 
8) Devlin, JW. et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 46(9), 2018, e825-73.
PubMed
9) Sigakis, MJ. et al. Ten Myths and Misconceptions Regarding Pain Management in the ICU. Crit Care Med. 43(11), 2015, 2468-78.
PubMed
10) Cantais, A. et al. Acetaminophen-Induced Changes in Systemic Blood Pressure in Critically Ill Patients:Results of a Multicenter Cohort Study. Crit Care Med. 44(12), 2016, 2192-8.
PubMed
P.82 掲載の参考文献
1) 日本神経学会監修. てんかん診療ガイドライン2018. 2018. https://www.neurology-jp.org/guidelinem/tenkan_2018.html (accessed 2019-09-24)
 
2) 日本神経学会監修. てんかん診療ガイドライン2018 追補版2022. https://www.neurology-jp.org/guidelinem/tenkan_tuiho_2018_ver2022.html (accessed 2023-08-01)
 
3) Treiman, DM. et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med. 339(12), 1998, 792-8.
 
4) Glauser, T. et al. Evidence-Based Guideline:Treatment of Convulsive Status Epilepticus in Children and Adults:Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 16(1), 2016, 48-61.
PubMed
5) Prasad, M. et al. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev. 2014(9), CD003723, 2014.
PubMed
6) Bohan, KH. et al. Anticonvulsant hypersensitivity syndrome:implications for pharmaceutical care. Pharmacotherapy. 27(10), 2007, 1425-39.
PubMed
P.87 掲載の参考文献
1) 日本版敗血症診療ガイドライン2020特別委員会. 日本版敗血症診療ガイドライン 2020. 日本集中治療医学会雑誌. 28(Suppl), 2021, S1-411.
 
2) 日本循環器学会/日本心不全学会. 急性・慢性心不全診療ガイドライン(2017年改訂版). https://www.j-circ.or.jp/cms/wpcontent/uploads/2017/06/JCS2017_tsutsui_h.pdf (accessed 2023-07-19)
 
3) Peberdy, MA. et al. Circulation. 123(6), 2011, e237.
 
4) Evans, L. et al. Surviving Sepsis Campaign:International Guidelines for Management of Sepsis and Septic Shock:2021. Crit Care Med. 49(11), 2021, e1063-1143.
PubMed
5) De Backer, D. et al. Dopamine versus norepinephrine in the treatment of septic shock:a meta-analysis. Crit Care Med. 40(3), 2012, 725-30.
PubMed
6) Cardenas-Garcia, J. et al. Safety of peripheral intravenous administration of vasoactive medication. J Hosp Med. 10(9), 2015, 581-5.
PubMed
7) Sharshar, T. et al. Circulating vasopressin levels in septic shock. Crit Care Med. 31(6), 2003, 1752-8.
PubMed
8) Russell, JA. et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 358(9), 2008, 877-87.
PubMed
9) Myburgh, JA. et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med. 34(12), 2008, 2226-34.
PubMed
10) Annane, D. et al. Corticosteroids for severe sepsis and septic shock:a systematic review and meta-analysis. BMJ. 329(7464), 2004, 480.
PubMed
11) Venkatesh, B. et al. Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. N Engl J Med. 378(9), 2018, 797-808.
PubMed
P.94 掲載の参考文献
1) Krajewski, ML. et al. Meta-analysis of high- versus low-chloride content in perioperative and critical care fluid resuscitation. Br J Surg. 102(1), 2015, 24-36.
PubMed
2) Yunos, NM. et al. Chloride-liberal vs. chloride-restrictive intravenous fluid administration and acute kidney injury:an extended analysis. Intensive Care Med. 41(2), 2015, 257-64.
PubMed
3) Liang, CS. et al. Metabolic control of the circulation. Effects of acetate and pyruvate. J Clin Invest. 62(5), 1978, 1029-38.
PubMed
4) Caironi, P. et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. 370(15), 2014, 1412-21.
 
5) Finfer, S. et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 350(22), 2004, 2247-56.
PubMed
6) Brunkhorst, FM. et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 358(2), 2008, 125-39.
PubMed
7) Perner A, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med. 367(2), 2012, 124-34.
 
8) Myburgh, JA. et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med. 367(20), 2012, 1901-11.
 
9) Wilcox, CX. Regulation of renal blood flow by plasma chloride. J Clin Invest. 71(3), 1983, 726-35.
 
10) Yunos NM, et al. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA. 308(15), 2012, 1566-72.
PubMed
11) Young, P. et al. Effect of a buffered crystalloid solution vs saline on Acute Kidney Injury Among Patients in the Intensive Care Unit:The SPLIT Randomized Clinical Trial. JAMA. 314(16), 2015, 1701-10.
PubMed
12) Semler, MW. et al. Balanced Crystalloids versus Saline in Critically Ill Adults. N Engl J Med. 378(9), 2018, 829-39.
PubMed
13) Zampieri, FG. et al. Effect of Intravenous Fluid Treatment With a Balanced Solution vs 0.9% Saline Solution on Mortality in Critically Ill Patients:The BaSICS Randomized Clinical Trial. JAMA. 326(9), 2021, 1-12.
 
14) Finfer S, et al. Balanced Multielectrolyte Solution versus Saline in Critically Ill Adults. N Engl J Med. 386(9), 2022, 815-26.
PubMed
15) Self, WH. et al. Clinical Effects of Balanced Crystalloids vs Saline in Adults With Diabetic Ketoacidosis:A Subgroup Analysis of Cluster Randomized Clinical Trials. JAMA Netw Open, 3(11), 2020, e2024596.
PubMed
16) 安村敏ほか. 科学的根拠に基づいたアルブミン製剤の使用ガイドライン(第2版). Japanese Journal of Transfusion and Cell Therapy. 64(6), 2018, 700-17.
Medical*Online
17) Myburgh, J. et al. SAFE Study Investigators. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med. 357(9), 2007, 874-84.
PubMed
P.101 掲載の参考文献
1) 日本循環器学会/日本心不全学会. 急性・慢性心不全診療ガイドライン(2017年改訂版). https://www.j-circ.or.jp/cms/wpcontent/uploads/2017/06/JCS2017_tsutsui_h.pdf (accessed 2023-05-17)
 
2) 日医工株式会社. ラシックス(R)注20mg. 医薬品インタビューフォーム. 2021年12月改訂(第10版). https://www.nichiiko.co.jp/medicine/file/55650/interview/55650_interview.pdf (accessed 2023-05-17)
 
3) 中村均ほか. 輸液配合変化のリスク・マネジメント. 外科と代謝・栄養. 51(5), 2017, 235-45.
Medical*Online
4) Nohria, A. et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 41(10), 2003, 1797-804.
PubMed
5) Mullens, W. et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 21(2), 2019, 137-55.
 
6) 大塚製薬株式会社. サムスカ(R)OD錠. 医薬品インタビューフォーム. 2022年9月改訂(第25版). https://www.otsuka-elibrary.jp/pdf_viewer/index.html?f=/file/1096/sam_if.pdf#page=1 (accessed 2023-05-17)
 
7) 柴垣有吾. 第2章 水代謝・ナトリウム代謝異常の診断と治療 4. 利尿薬の使い方. より理解を深める! 体液電解質異常と輸液. 東京, 中外医学社, 2007, 28-33.
 
8) Ellison, DH. et al. Diuretic Treatment in Heart Failure. N Engl J Med. 377(20), 2017, 1964-75.
PubMed
9) Li, T. et al. Hypernatremia induced by low-dose Tolvaptan in a Patient with refractory heart failure:A case report. Medicine (Baltimore). 98(27), 2019, e16229.
 
10) 原晃. 薬剤による難聴の臨床. 日本医事新報. (4140), 2003, 42-7.
Medical*Online
11) Guo, J. et al. Protection of Hair Cells from Ototoxic Drug-Induced Hearing Loss. Adv Exp Med Biol. 1130, 2019, 17-36.
PubMed
12) Asare K. Management of loop diuretic resistance in the intensive care unit. Am J Health Syst Pharm. 66(18), 2009, 1635-40.
PubMed
13) JK. Aronson. Meyler's Side Effects of Drugs:The International Encyclopedia of Adverse Drug Reactions and Interactions, 16th Edition. Amsterdam, Elsevier Science, 2016, 466-74.
 
P.107 掲載の参考文献
1) 日本蘇生協議会監修. JRC蘇生ガイドライン2020. 東京, 医学書院, 2021, 532p.
 
2) 日本循環器学会/日本不整脈心電学会. 2020年改訂版 不整脈薬物治療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/01/JCS2020_Ono.pdf (accessed 2023-07-19)
 
3) Kudenchuk, PJ. et al. Amiodarone for Resuscitation after Out-of-Hospital Cardiac Arrest Due to Ventricular Fibrillation. N Engl J Med. 341(12), 1999, 871-8.
PubMed
4) Kudenchuk, PJ. et al. Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest. N Engl J Med. 374(18), 2016, 1711-22.
 
5) Ikeda, T. et al. Efficacy and Safety of the Ultra-Short-Acting β1-Selective Blocker Landiolol in Patients With Recurrent Hemodynamically Unstable Ventricular Tachyarrhymias - Outcomes of J-Land II Study. Circ J. 83(7), 2019, 1456-62.
 
6) Kakihana, Y. et al. Efficacy and safety of landiolol, an ultra-short-acting β 1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S):a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 8(9), 2020, 863-72.
 
7) Karlis, G. et al. Nifekalant Versus Amiodarone in the Treatment of Cardiac Arrest:an Experimental Study in a Swine Model of Prolonged Ventricular Fibrillation. Cardiovasc Drugs Ther. 29(5), 2015, 425-31.
 
P.112 掲載の参考文献
1) 日本循環器学会/日本不整脈心電学会合同ガイドライン. 2020年改訂版 不整脈薬物治療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/01/JCS2020_Ono.pdf (accessed 2023-07-19)
 
P.117 掲載の参考文献
1) 日本循環器学会ほか. 急性冠症候群ガイドライン(2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2018/11/JCS2018_kimura.pdf (accessed 2023-05-01)
 
2) アーチスト. 医薬品インタビューフォーム. 2023年7月改訂(第18版). https://www.medicalcommunity.jp/filedsp/products$druginfo$artist$if/field_file_pdf (accessed 2023-07-24)
 
3) メインテート. 医薬品インタビューフォーム. 2013年9月改訂(第12版). https://medical.mt-pharma.co.jp/di/file/if/f_mnt_a.pdf (accessed 2023-07-24)
 
4) Beta-Blocker Evaluation of Survival Trial Investigators. et al. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 344(22), 2001, 1659-67.
 
5) MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 353(9169), 1999, 2001-7.
 
6) Laurence Brunton ほか編. グッドマン・ギルマン薬理書〈上〉:薬物治療の基礎と臨床. 第12版, 東京, 廣川書店, 2013, 1480p.
 
7) Morales, DR. et al. Adverse respiratory effect of acute β-blocker exposure in asthma:a systematic review and meta-analysis of randomized controlled trials. Chest. 145(4), 2014, 779-86.
 
8) Ripley, TL. et al. β-blockers:a review of their pharma cological and physiological diversity in hypertension. Ann Pharmacother. 48(6), 2014, 723-33.
 
9) Bangalore, S. et al. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 100(8), 2007, 1254-62.
 
10) Bakris, GL. et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension:a randomized controlled trial. JAMA. 292(18), 2004, 2227-36.
PubMed
11) 日本高血圧学会. 高血圧治療ガイドライン2019. 日本高血圧学会高血圧治療ガイドライン作成委員会編. https://www.jpnsh.jp/data/jsh2019/JSH2019_hp.pdf (accessed 2023-05-01)
 
P.124 掲載の参考文献
1) 日本循環器学会ほか. 2020年改訂版 不整脈薬物治療ガイドライン. http://www.j-circ.or.jp/cms/wp-content/uploads/2020/01/JCS2020_Ono.pdf (accessed 2023-05-01)
 
2) Gage, BF. et al. Validation of clinical classification schemes for predicting stroke:results from the National Registry of Atrial Fibrillation. JAMA. 285, (22) 2001, 2864-70.
 
3) January, CT. et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. S0735-1097(19), 2019, 30209-8.
 
4) Lip, GY. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach:the euro heart survey on atrial fibrillation. Chest. 137(2), 2010, 263-72.
PubMed
5) European Heart Rhythm Association. et al. Guidelines for the management of atrial fibrillation:the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 31(19), 2010, 2369-429.
 
6) Pisters, R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation:the Euro Heart Survey. Chest. 138(5), 2010, 1093-100.
PubMed
7) 医薬品医療機器総合機構. https://www.pmda.go.jp/files/000143273.pdf (accessed 2023-07-26)
 
8) Wiggins, BS. et al. Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin. Pharmacotherapy. 36(2), 2016, e5-7.
 
9) Hellwig, T. et al. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants:what do they mean for patients with atrial fibrillation? Ann Pharmacother. 47(11), 2013, 1478-87.
PubMed
10) Makris, M. Optimisation of the prothrombin complex concentrate dose for warfarin reversal. Thromb Res. 115(6), 2005, 451-3.
PubMed
11) Gulseth, MP. Overview of direct oral anticoagulant therapy reversal. Am J Health Syst Pharm. 73(10 Suppl 2), 2016, S5-S13.
 
12) Pollack CV Jr. et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 373(6), 2015, 511-20.
PubMed
13) アンデキサネット アルファ(オンデキサ(R)静注用200mg)添付文書. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/670227_3399414D1022_2_01 (accessed 2023-05-01)
 
P.129 掲載の参考文献
1) 日本脳卒中学会 脳卒中ガイドライン委員会編. 脳卒中治療ガイドライン2021〔改訂2023〕. 東京, 協和企画, 2023, 332p.
 
2) CAST:randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 349(9066), 1997, 1641-9.
 
3) Wang, Y. et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 369(1), 2013, 11-9.
 
4) Johnston, SC. et al. Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 379(3), 2018, 215-25.
 
5) サノフィ株式会社. プラビックス(R)錠25mg/プラビックス(R)錠75mg添付文書. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/780069_3399008F1025_1_30 (accessed 2023-07-28)
 
6) Kristen, L. et al. High-dose clopidogrel loading in percutaneous coronary intervention. Ann Pharmacother. 39(5), 2005, 918-22.
 
7) Lars, W. P2Y (12) inhibitors:differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J. 30(16), 2009, 1964-77.
 
P.135 掲載の参考文献
1) CSL Behring. ケイセントラ(R)投与量換算シミュレーター. https://csl-info.com/kcentra/howto/ (accessed 2023-05-05)
 
2) アストラゼネカ. オンデキサ(R)静注用200mg調製方法・投与方法. https://med.astrazeneca.co.jp/medical/product/ond_howto.html (accessed 2023-05-05)
 
3) Kushimoto, S. et al. Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures:a prospective, open-label, single-arm phase 3b study. Int J Hematol. 106(6), 2017, 777-86.
 
4) Goldstein, JN. et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions:a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 385(9982), 2015, 2077-87.
PubMed
5) Sarode, R. et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding:a randomized, plasma-controlled, phase III b study. Circulation. 128(11), 2013, 1234-43.
PubMed
6) Sin, JH. et al. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery:A retrospective evaluation. J Crit Care. 36, 2016, 166-72.
PubMed
7) プリズバインド(R)静注液2.5g. 医薬品インタビューフォーム. 2022年11月改訂(第5版). https://www.info.pmda.go.jp/go/interview/1/650168_3399412A1027_1_22Y_1F.pdf (accessed 2023-05-05)
 
8) Connolly, SJ. et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 380(14), 2019, 1326-35.
PubMed
9) Milling, TJ Jr. et al. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. Circulation. 147(13), 2023, 1026-38.
PubMed
10) アストラゼネカ社. オンデキサ(R)投与方法の解説. https://med.astrazeneca.co.jp/content/dam/physician-services/Japan/medical/product/ond_howto/download/ond_howto02.pdf (accessed 2023-05-05)
 
11) Ansell, JE. et al. Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thromb Haemost. 117(2), 2017, 238-45.
PubMed
P.142 掲載の参考文献
1) アストラゼネカ株式会社. ロケルマ懸濁用散分包5g/10g患者向医薬品ガイド. 2022年3月更新. https://www.info.pmda.go.jp/downfiles/guide/ph/670227_2190040B1020_1_01G.pdf (accessed 2023-06-01)
 
2) 遠藤慶太ほか. 高カリウム血症. 日本内科学会雑誌. 111(5), 2022, 926-33.
 
3) Cooper, LB. et al. Clinical and research implications of serum versus plasma potassium measurements. Eur J Heart Fail. 21(4), 2019, 536-7.
PubMed
4) Noori, N. et al. Dietary potassium intake and mortality in long-term hemodialysis patients. Am J Kidney Dis. 56(2), 2010, 338-47.
PubMed
5) kidney Disease:Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 102(55), 2022, D1-127.
 
P.149 掲載の参考文献
1) 日本糖尿病学会 ビグアナイド薬の適正使用に関する委員会. メトホルミンの適正使用に関するRecommendation. 2020年3月18日改訂. http://www.jds.or.jp/uploads/files/recommendation/metformin.pdf
 
2) 日本糖尿病学会:コンセンサスステートメント策定に関する委員会. 「2型糖尿病の薬物療法のアルゴリズム」. 糖尿病. 65(8), 2022, 419-34.
 
P.155 掲載の参考文献
1) Watanabe, AK. et al. Multicenter survey on hospital-acquired pneumonia and the clinical efficacy of first- line antibiotics in Japan. Intern Med. 47(4), 2008, 245-54.
 
2) Kalil, AC. et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia:2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 63(5), 2016, e61-e111.
 
3) 日本化学療法学会/日本感染症学会. MRSA感染症の治療ガイドライン改訂版 2019. https://www.kansensho.or.jp/uploads/files/guidelines/guideline_mrsa_2019revised-booklet.pdf (accessed 2023-07-26)
 
4) Silverman, JA. et al. Inhibition of daptomycin by pulmonary surfactant:in vitro modeling and clinical impact. J Infect Dis. 191(12), 2005, 2149-52.
PubMed
5) Wu, VC. et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 42(1), 2006, 66-72.
PubMed
6) Takahashi, Y. et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother. 17(3), 2011, 382-7.
PubMed
7) Hanai, Y. et al. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J Infect Chemother. 22(8), 2016, 536-42.
PubMed
8) Rubinstein, E. et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia:a randomized, double-blind, multicenter study. Clin Infect Dis. 32(3), 2001, 402-12.
PubMed
9) Wunderink, RG. et al. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther. 25(3), 2003, 980-92.
PubMed
10) Wang, Y. et al. Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia:a systematic review employing meta-analysis. Eur J Clin Pharmacol. 71(1), 2015, 107-15.
PubMed
11) Chava net, P. The ZEPHyR study:a randomized comparison of linezolid and vancomycin for MRSA pneumonia. Med Mal Infect. 43(11-12), 2013, 451-5.
 
12) Liu, C. et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin- resistant Staphylococcusaureus infections in adults and children. Clin Infect Dis. 52(3), 2011, e18-55.
 
13) Tsutsuura, M. et al. The monitoring of vancomycin:a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing. BMC Infect Dis. 21(1), 2021, 153.
PubMed
14) Sivagnanam, S. et al. Red man syndrome. Crit Care. 7(2), 2003, 119-20.
PubMed
15) Korman, TM. et al. Risk factors for adverse cutaneous reactions associated with intravenous vancomycin. J Antimicrob Chemother. 39(3), 1997, 371-81.
PubMed
P.160 掲載の参考文献
1) 日本医真菌学会. 侵襲性カンジダ症の診断・治療ガイドライン. 2013.
 
2) Wisplinghoff, H. et al. Nosocomial bloodstream infections in US hospitals:analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 39(3), 2004, 309-17.
PubMed
3) Lortholary, O. et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med. 40(9), 2014, 1303-12.
PubMed
4) Bassetti, M. et al. A multicenter study of septic shock due to candidemia:outcomes and predictors of mortality. Intensive Care Med. 40(6), 2014, 839-45.
 
5) Krishna, R. et al. Should all patients with candidaemia have an ophthalmic examination to rule out ocular candidiasis? Eye. 14(Pt1), 2000, 30-4.
 
6) 深在性真菌症のガイドライン作成委員会編. 深在性真菌症の診断・治療ガイドライン2014. 東京, 協和企画, 2014, 261p.
 
7) Pappas, PG. et al. Clinical Practice Guideline for the Management of Candidiasis:2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 62(4), 2016, e1-50.
 
8) Oude Lashof, AM. et al. Ocular manifestations of candidemia. Clin Infect Dis. 53(3), 2011, 262-8.
PubMed
9) Dozier, CC, et al. Fungal eye disease at a tertiary care center:the utility of routine inpatient consultation. Ophthalmology. 118(8), 2011, 1671-6.
 
10) Elizabeth, S. et al. Pharmacology of Systemic Antifungal Agents. Clin Infect Dis. 43(Suppl1), 2006, S28-39.
 
P.166 掲載の参考文献
1) Kahn, SR. et al. Prevention of VTE in nonsurgical patients:Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141(2 Suppl), 2012, e195Se226S.
 
2) Geerts, W. et al. Prevention of venous thromboembolism in the ICU. Chest. 124(6 Suppl), 2003, 357S-63S.
 
3) Geerts, W. et al. Venous thromboembolism and its prevention in critical care. J Crit Care. 17(2), 2002, 95-104.
PubMed
4) Barbar, S. et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism:the Padua Prediction Score. J Thromb Haemost. 8(11), 2010, 2450-7.
 
5) Goldhaber, SZ. et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 365(23), 2011, 2167-77.
PubMed
6) Carter, C. et al. Clinical Experience With Pharmacological Venous Thromboembolism Prophylaxis in the Underweight and Critically III. Ann Pharmacotherapy. 50(10), 2016, 832-9.
 
P.174 掲載の参考文献
1) 佐川賢一. 錠剤・カプセル剤粉砕ハンドブック. 第8版. 東京, じほう, 2019, 324-27.
 
2) 倉田なおみ. 内服薬 経管投与ハンドブック. 第4版. 東京, じほう, 2020, 252-3.
 
3) LTLファーマ株式会社. ガスター注射液(R)10mg・20mg添付文書. 2019年8月改訂(第1版).
 
4) 日本集中治療医学会重症患者の栄養管理ガイドライン作成委員会. 日本版重症患者の栄養療法ガイドライン. 日本集中治療医学会雑誌. 23, 2016, 185-281.
 
5) Cook, DJ. et al. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care. 5(6), 2001, 368-75.
PubMed
6) Ye, Z. et al. Gastrointestinal bleeding prophylaxis for critically ill patients:a clinical practice guideline. BMJ. 368, 2020, l6722.
PubMed
7) Toews, I. et al. Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units. Cochrane Database Syst Rev. 6(6), 2018, CD008687.
PubMed
8) Krag, M. et al. Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients. A systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med. 40(1), 2014, 11-22.
 
9) Reynolds, PM. et al. Re-evaluating the Utility of Stress Ulcer Prophylaxis in the Critically Ill Patient:A Clinical Scenario-Based Meta-Analysis. Pharmacotherapy. 39(3), 2019, 408-20.
 
10) Wang, Y. et al. Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients:systematic review and network meta-analysis. BMJ. 368, 2020, l6744.
PubMed
11) Feldman, M. et al. Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases. N Engl J Med. 323(24), 1990, 1672-80.
PubMed
12) Krag, M. et al. Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU. N Engl J Med. 379(23), 2018, 2199-208.
PubMed
13) PEPTIC Investigators for the Australian and New Zealand Intensive Care Society Clinical Trials Group. Young, PJ. et al. Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation:The PEPTIC Randomized Clinical Trial. JAMA. 323(7), 2020, 616-26.
 
14) Eom, CS. et al. Use of acid-suppressive drugs and risk of pneumonia:a systematic review and meta-analysis. CMAJ. 183(3), 2011, 310-9.
PubMed
15) Janarthanan, S. et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy:a meta-analysis. Am J Gastroenterol. 107(7), 2012, 1001-10.
PubMed
16) Finkenstedt A, et al. Stress ulcer prophylaxis:Is mortality a useful endpoint?. Intensive Care Med. 46(11), 2020, 2058-60.
PubMed
17) Lazarus, B. et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 176(2), 2016, 238-46.
PubMed
18) Hinrichsen, H. et al. Clinical aspects of cardiovascular effects of H2-receptor antagonists. Eur J Clin Invest, 25(Suppl 1), 1995, 47-56.
 
19) Lee, KW. et al. Famotidine and long QT syndrome. Am J Cardiol. 93(10), 2004, 1325-7.
PubMed
20) Andersohn, F. et al. Systematic review:agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 146(9), 2007, 657-65.
PubMed
21) Shiddapur, A. et al. Association of Histamine-2 Blockers and Proton-Pump Inhibitors With Delirium Development in Critically Ill Adults:A Retrospective Cohort Study. Crit Care Explor. 3(8), 2021, e0507.
PubMed
22) Fisher, AA. et al. Nephrotoxicity and hepatotoxicity of histamine H2 receptor antagonists. Drug Saf. 24(1), 2001, 39-57.
PubMed
23) Huang, JQ. et al. pH, healing rate and symptom relief in acid-related diseases. Yale J Biol Med. 1996, 69(2), 159-74.
PubMed
24) Kirchheiner J, et al. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 65(1), 2009, 19-31.
 
25) Graham, DY. et al. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol. 16(6), 2018, 800-8.
PubMed

書評

最近チェックした商品履歴

Loading...